
    
      Upon completion of 24 weeks of GI198745 0.05 mg, 0.5 mg, 2.5 mg, or placebo therapy in study
      ARI20005, subjects are enrolled into an extension phase and are continued on the same therapy
      once daily for up to further 28 weeks, followed by up to 16 weeks of post-dosing assessments.
    
  